These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33896277)

  • 1. Stability of Cell-Penetrating Peptide anti-VEGF Formulations for the Treatment of Age-Related Macular Degeneration.
    Nikoi ND; Berwick M; Bryant JA; Riordan L; Slope L; Peacock AFA; de Cogan F
    Curr Eye Res; 2021 May; 46(5):751-757. PubMed ID: 33896277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides.
    de Cogan F; Hill LJ; Lynch A; Morgan-Warren PJ; Lechner J; Berwick MR; Peacock AFA; Chen M; Scott RAH; Xu H; Logan A
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2578-2590. PubMed ID: 28494491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab.
    Das T; Volety S; Ahsan SM; Thakur AK; Sharma S; Padhi TR; Basu S; Rao ChM
    Clin Exp Ophthalmol; 2015 Jul; 43(5):466-73. PubMed ID: 25545882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration.
    Sugimoto MAA; Toledo VPCP; Cunha MRR; Carregal VM; Jorge R; Leão P; Fialho SL; Silva-Cunha A
    Arq Bras Oftalmol; 2017; 80(2):108-113. PubMed ID: 28591284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
    Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
    Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology.
    Formica ML; Awde Alfonso HG; Palma SD
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00723. PubMed ID: 33694304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration.
    Luaces-Rodríguez A; Mondelo-García C; Zarra-Ferro I; González-Barcia M; Aguiar P; Fernández-Ferreiro A; Otero-Espinar FJ
    Int J Pharm; 2020 Jan; 573():118767. PubMed ID: 31669558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months.
    Chen YH; Wu PC; Shiea J; Lo LH; Wu YC; Kuo HK
    J Ocul Pharmacol Ther; 2009 Feb; 25(1):65-9. PubMed ID: 19232008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
    Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE
    Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
    Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab.
    Wang D; Choi KS; Lee SJ
    Korean J Ophthalmol; 2014 Feb; 28(1):32-8. PubMed ID: 24505199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS; Verma N
    Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Storey PP; Ho V; Yeh S; Reddy S; Fang-Yen NH; Pequignot E; Leiby BE; Fineman M; Garg S; Hubbard GB; Hsu J
    Retina; 2015 Oct; 35(10):1992-2000. PubMed ID: 26035396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration.
    Paul M; Vieillard V; Roumi E; Cauvin A; Despiau MC; Laurent M; Astier A
    Ann Pharm Fr; 2012 May; 70(3):139-54. PubMed ID: 22655582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.